Publications by authors named "Jose Fernando do Prado Moura"
Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on : Case Series and Literature Review of Treatment.
Nicholas P Giustini Sandip Pravin Patel Nathaniel J Myall José Fernando do Prado Moura Amit Kulkarni
JCO Precis Oncol
August 2022
The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis.
View Article and Find Full Text PDF